Ginkgo Datapoints, Apheris, AbbVie, and Others Form Antibody Developability Consortium

10:31 AM EDT, 09/29/2026 (MT Newswires) -- Ginkgo Bioworks' (DNA) Datapoints and Apheris said Tuesday that AbbVie (ABBV), argenx (ARGX), Lundbeck, and Takeda (TAK) will join them as founding members of the Antibody Developability Consortium. The consortium is designed to help pharmaceutical and biotech companies predict manufacturability and developability risks earlier by building the field's largest standardized antibody developability dataset, according to a statement. The companies said that each founding member will contribute proprietary antibody sequences, with Ginkgo Datapoints filling any remaining capacity from publicly available sources to reach a total of 10,000 antibodies. The consortium is targeting an initial dataset by early 2027, they added. Price: 11.01, Change: +0.55, Percent Change: +5.26